Early Rehabilitation After Transfemoral Amputation in Moderately Active Patients
Launched by MEDIAN · Sep 13, 2023
Trial Information
Current as of September 12, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the benefits of early rehabilitation for patients who have undergone a transfemoral amputation, which means their leg has been removed above the knee. The focus is on how quickly patients can start their rehabilitation while using a special type of prosthetic leg called a microprocessor-controlled prosthesis (specifically the Kenevo model). The goal is to see if following treatment guidelines closely can help patients recover better and faster.
To participate in this study, you need to be between the ages of 65 and 74, have recently undergone a transfemoral amputation or knee disarticulation, and be able to communicate in German. You'll also need to be able to give your consent to participate and weigh no more than 125 kg, which is the weight limit for the prosthetic device being used. If you join the trial, you can expect to receive early rehabilitation support while using the advanced prosthesis, helping you adapt and regain mobility. This trial is currently looking for participants, so if you or someone you know might be eligible, it could be a great opportunity to receive specialized care during recovery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • inpatient rehabilitation stay after transfemoral amputation or knee disarticulation
- • anticipated K-level 1 or 2
- • body weight no more than 125kg (authorized body weight for prosthetic device)
- • German speaking
- • able to give informed consent
- Exclusion Criteria:
- • non-German speaking
- • not able to give informed consent
- • body weight over 125kg
About Median
Median is a forward-thinking clinical trial sponsor dedicated to advancing healthcare through innovative research and development. With a focus on precision medicine, Median specializes in designing and conducting clinical trials that leverage cutting-edge technologies and methodologies. The organization prioritizes patient-centric approaches, ensuring that trials are aligned with the needs of diverse populations. By fostering collaborations with academic institutions, healthcare providers, and industry partners, Median aims to accelerate the development of new therapies and improve patient outcomes across various therapeutic areas. Their commitment to excellence and integrity positions them as a trusted leader in the clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Wiesbaden, Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported